Chair: Michael Gnant, Austria

Intruduction
Michael Gnant, Austria
Development and Validation of Intrinsic Subtyping for the Clinic
Charles M. Perou, USA
Value of Prosigna® genomic signature for management of early breast cancer
Nadia Harbeck, Germany
Near the patient innovation: Prosigna® decentralized testing in cancer centers network, and beyond
Frederique Penault-Llorca, France